Crescent Biopharma (CBIO) EPS (Weighted Average and Diluted) (2013 - 2024)
Crescent Biopharma (CBIO) reported EPS (Weighted Average and Diluted) of -$0.11 for Q4 2024, up 21.43% year-over-year from -$0.09 in Q1 2024, and up 26.67% on a QoQ basis from -$0.15 in Q3 2024.
Crescent Biopharma (CBIO) has 10 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.11 in Q4 2024.
- Quarterly EPS (Weighted Average and Diluted) rose 21.43% year-over-year to -$0.11 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$0.46 (up 20.69% YoY) and the FY2024 annual result came in at -$0.59, down 1.72% from the prior year.
- EPS (Weighted Average and Diluted) grew to -$0.11 in Q4 2024 per CBIO's latest filing, from -$0.15 in the prior quarter.
- Across five years, EPS (Weighted Average and Diluted) topped out at -$0.04 in Q1 2024 and bottomed at -$0.34 in Q4 2020.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.17 (2023), against an average of -$0.21.
- Peak annual rise in EPS (Weighted Average and Diluted) reached 76.47% in 2024, while the deepest fall reached 23.08% in 2024.
- Tracing CBIO's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.34 in 2020, then gained by 3.05% to -$0.33 in 2021, then soared by 42.42% to -$0.19 in 2022, then gained by 26.32% to -$0.14 in 2023, then increased by 21.43% to -$0.11 in 2024.
- Per Business Quant, the three latest CBIO EPS (Weighted Average and Diluted) figures stand at -$0.11 (Q4 2024), -$0.15 (Q3 2024), and -$0.16 (Q2 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -4.43 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 3,086.42 |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 0.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 4.02 |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 6.75 |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.51 |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -0.11 |
| Sep 30, 2024 | -0.15 |
| Jun 30, 2024 | -0.16 |
| Mar 31, 2024 | -0.04 |
| Dec 31, 2023 | -0.14 |
| Sep 30, 2023 | -0.14 |
| Jun 30, 2023 | -0.13 |
| Mar 31, 2023 | -0.17 |
| Dec 31, 2022 | -0.19 |
| Sep 30, 2022 | -0.16 |
| Jun 30, 2022 | -0.25 |
| Mar 31, 2022 | -0.28 |
| Dec 31, 2021 | -0.33 |
| Sep 30, 2021 | -0.34 |
| Jun 30, 2021 | -0.28 |
| Mar 31, 2021 | -0.28 |
| Dec 31, 2020 | -0.34 |
| Dec 31, 2019 | -0.34 |
| Jun 30, 2016 | -0.41 |
| Dec 31, 2015 | -0.47 |
| Sep 30, 2015 | -0.38 |
| Jun 30, 2015 | 0.51 |
| Mar 31, 2015 | -0.37 |
| Dec 31, 2014 | -0.39 |
| Sep 30, 2014 | -0.35 |
| Jun 30, 2014 | 0.39 |
| Mar 31, 2014 | -0.30 |
| Dec 31, 2013 | -2.80 |
| Sep 30, 2013 | -3.00 |
| Jun 30, 2013 | -3.70 |
| Mar 31, 2013 | 0.04 |